Scancell Holdings PLC (AIM:SCLP, OTC:SCNLF), a developer of immunotherapies for cancer and infectious diseases, has reached a pivotal milestone in its.
Scancell Holdings PLC announced on Tuesday that the first patient of a new trial cohort has been dosed with its iSCIB1+ therapeutic.
The Oxford, England-based developer of immunotherapies for.
Scancell Holdings plc (LON:SCLP – Get Free Report)’s stock price crossed below its two hundred day moving average during trading on Friday . The stock has a two hundred day moving average of GBX 11.79 ($0.15) and traded as low as GBX 11.36 ($0.14). Scancell shares last traded at GBX 11.63 ($0.15), with a volume […]